Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) EBITDA (2016 - 2025)

ProQR Therapeutics' EBITDA history spans 5 years, with the latest figure at -$10.6 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 1.7% to -$10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$23.2 million, a 243.95% decrease, with the full-year FY2025 number at -$47.4 million, down 60.16% from a year prior.
  • EBITDA hit -$10.6 million in Q4 2025 for ProQR Therapeutics, down from $12.9 million in the prior quarter.
  • Over the last five years, EBITDA for PRQR hit a ceiling of $20.7 million in Q4 2021 and a floor of -$22.9 million in Q3 2022.
  • Historically, EBITDA has averaged -$1.6 million across 5 years, with a median of -$7.4 million in 2023.
  • Biggest five-year swings in EBITDA: skyrocketed 205.78% in 2022 and later crashed 618.55% in 2025.
  • Tracing PRQR's EBITDA over 5 years: stood at $20.7 million in 2021, then tumbled by 161.46% to -$12.7 million in 2022, then surged by 46.95% to -$6.7 million in 2023, then plummeted by 59.73% to -$10.8 million in 2024, then grew by 1.7% to -$10.6 million in 2025.
  • Business Quant data shows EBITDA for PRQR at -$10.6 million in Q4 2025, $12.9 million in Q3 2025, and -$14.6 million in Q2 2025.